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Abstract: The aim of this study was to check effectiveness of drug-eluting stents for prevention of restenosis resulting from neointimal
hyperplasia. Twenty-one sirolimus-eluting stents (SESs) and bare metal stents (BMSs; control) were compared by implantation into left
and right balloon-injured external iliac arteries of New Zealand White rabbits, respectively. Under general anesthesia and angiography,
using 3-mm coronary balloon catheters, stents were successfully deployed. Anticoagulant therapy was not given to any animal. Rabbits
were allotted into three groups at 7, 14, and 21 days (7 rabbits in each group). Each stented vessel of sacrificed rabbits was subjected to a
resin-embedding technique and methyl methacrylate sections were obtained using a tungsten carbide knife for staining. In histological
examination, SESs showed marked reductions in almost all parameters. Morphometric results showed that arteries with SESs had a
larger luminal area (P < 0.0001), lower intimal (P < 0.001) and medial (P < 0.001) thickness, and lower intimal index (P < 0.003) as
opposed to arteries stented with BMSs. Luminal narrowing in SESs was 0% and reendothelialization was similar in both stented groups
(90.48%). SESs showed marked reduction in nonocclusive peristrut fibrin deposition versus BMSs. Thus, the SES was more effective for
prevention of restenosis than the BMS in rabbit.
Key words: Bare metal, external iliac artery, neointimal hyperplasia, rabbits, sirolimus-eluting stent

1. Introduction
Cardiovascular medicine is changing rapidly with the
development, testing, and introduction of new diagnostic
and therapeutic techniques. Percutaneous coronary
intervention with stents is the method of choice for
revascularization in the management of coronary artery
disease. However, restenosis is a major drawback of this
method (1–4). The percutaneous implantation of bare metal
stents (BMSs) is associated with a high rate of restenosis
(5–7). In-stent restenosis is due to neointimal hyperplasia
as a result of smooth muscle migration and proliferation
as well as extracellular matrix deposition. Elastic vascular
recoil and constrictive arterial remodeling also contribute.
Mechanical injury of the arterial wall occurred during
operation by stent. This incites an acute inflammation in
the vessel wall with the release of cytokines and growth
factors, which in turn induce multiple signaling pathways
* Correspondence: dratulvet07@yahoo.co.in

to activate smooth muscle migration and proliferation (8).
Drug-eluting stents (DESs) improve the clinical
outcome after percutaneous coronary intervention as
one of the greatest accomplishments in cardiology (9,10).
DESs loaded with antiinflammatory, antiproliferative,
or prohealing drugs have reduced the rates of restenosis
compared with the previously used BMSs, thereby
initiating a revolution in the treatment of coronary artery
disease (11,12). Preclinical testing in animal models is the
mainstay of the regulatory process to determine the safety
and efficacy of these stents before human use. Porcine and
rabbit models are extensively evaluated as they predict
human responses as the stages of healing are similar, even
though the temporal response to healing is significantly
prolonged in humans (13). The pathophysiology of stent
is related to the histological and histomorphometric
evaluation of stented arteries (14).
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The sirolimus-eluting stent (SES) is a metal stent
coated with sirolimus blended with synthetic polymers.
After stent implantation, sirolimus is slowly released,
causing localized cytostatic inhibition of proliferation of
vascular smooth muscle cells in the peristent arterial wall
over a period of about 1 month. Only minimal amounts
of sirolimus enter the bloodstream and these appear to be
insufficient to be of clinical relevance.
The sirolimus-eluting coronary stent was approved in
Europe in April 2002; in the United States, FDA approval
followed in April 2003. The man feasibility studies were
presented and several randomized, controlled trials have
documented the profound antiproliferative effects of
sirolimus, a macrolide antibiotic and potent cytostatic
inhibitor of smooth muscle cell proliferation. The body of
clinical evidence was increased by more complex lesions
(such as in-stent restenosis, small vessels, and chronic
total occlusions) and “high-risk” patients such as those
with diabetes. As a result of numerous single-center and
multicenter national and international studies, the safety
and efficacy of sirolimus-eluting coronary stents have been
subjected to close scrutiny.
The aim of this study is to determine the effectiveness
of DESs for prevention of restenosis resulting from
neointimal hyperplasia.
2. Materials and methods
2.1. Animals
The project was approved by the Institutional Animal
Ethics Committee of Anand Veterinary College, Anand,
India (Project No. 2008/Surgery/51, Dt. 22.10.2008). The
animals received humane care in compliance with the
principles of Laboratory Animal Care formulated by the
National Research Center and the Guide for the Care and
Use of Laboratory Animals of the National Institutes of
Health.
2.2. Drug profile of stent
In the present experimental study, the concentration of
rapamycin on stents (3 × 13 mm) was 65 µg. Total amounts
of drug and polymer on the DES were 23.76% and 76.23%,
respectively.
2.3. Procedure
In 21 New Zealand White adult rabbits (Oryctolagus
cuniculus) of either sex, of >8 months of age with
average mean body weight 1.591 kg (range: 1.0–2.411
kg), sirolimus-eluting (FlexyRap, Sahajanand Laser
Technology Ltd., Gandhinagar, Gujarat, India) and bare
metal (FlexyStar; Sahajanand Laser Technology Ltd.)
stents were deployed in the left and right balloon-injured
external iliac arteries, respectively. Rabbits were allotted to
3 groups (A, B, C) of 7 each to study the stent occlusion
rates at 7 (Group A), 14 (Group B), and 21 (Group C)
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days. One day prior to the experimentation, the animals
were weighed and the ventral neck region was prepared
for aseptic intervention, and the diet was reduced to half
on the day of operation. Rabbits were premedicated with
injectable meloxicam at 0.05 mg/kg and enrofloxacin at 5
mg/kg body weight intramuscularly and anesthetized with
a mixture of injectable diazepam (0.5 mg/kg), injectable
ketamine HCl (40 mg/kg), and injectable xylazine HCl
(2.3 mg/kg) given intramuscularly. Incremental doses
were used for maintenance of anesthesia.
2.3.1. Antegrade iliac artery stent implantation
Antegrade iliac artery stenting was performed as previously
described (12,13,15). A small skin incision on the ventral
side of the left neck was followed by separation of muscles
until left carotid artery pulsation was felt. The left internal
carotid artery was secured with Vicryl 3-0 threads in
cranial, middle, and caudal positions (Figure 1). Two drops
each of lignocaine HCl and papaverine HCl were instilled
over the carotid artery. The artery was cannulated using
a 24-G Jelco intra-cath guide wire and advanced under
fluoroscopic imaging. After obtaining a steady hold upon
the carotid artery, the cannula (5-Fr introducer sheath) was
progressed in the carotid artery for iliac stenting (Figure
2). The guide wire was looped initially into the ascending
aorta and then guided gently into the descending aorta.
The soft-tip guide catheter and guide wire were oriented
dorsally towards the common iliac artery via cranial,
caudal aorta, and aortic quadrification. The left external
iliac artery was wired first and a noncompliant coronary
balloon angioplasty catheter of 3 mm in diameter was
advanced under fluoroscopic imaging to the proximal
common iliac artery, where it was inflated to 8 atm for 60
s to induce deep arterial injury. The guide wire was then
advanced into the proximal portion of the right external
iliac artery for balloon injury. The balloon catheter was
carefully removed while the guide wire remained in place.
The stent on the metallic stent platform delivery system

Figure 1. Triple ligation of carotid artery.
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Figure 2. Insertion of cannula.

was advanced to the distal portion of the iliac artery using
the guide wire; thereafter, the SES was deployed at the
site of arterial injury. The guide wire was taken out and
repositioned into the left iliac artery for BMS deployment.
The BMSs were also deployed similarly at the arterial injury
in the left external iliac artery. The balloon was slowly
taken out under fluoroscopic imaging after deflating.
Successful deployments of stents (Figure 3) were verified
by fluoroscopic imaging and the stent delivery catheter was
removed. The carotid artery was ligated with Vicryl 3-0 and
neck musculature was sutured using an interrupted suture
pattern with Vicryl 3-0 and skin with silk 2-0. Rabbits
received enrofloxacin (5 mg/kg IM) and meloxicam (0.05
mg/kg IM) for 3 days after stent implantation. None of the
animals were treated with anticoagulant or antiplatelet

Figure 3. X-ray showing stents in both iliac arteries of rabbit.

therapy after the operation. Patency of the vessels after
stent implantation was determined in one rabbit from
each group (7, 14, and 21 days) by a dorsal intraoperative
angiography with diluted angiografin (German Remedies,
Zydus Cadila Health Care Ltd.). After surgery rabbits were
allowed to recover in a warm environment under a heating
lamp to maintain body temperature. Green pellets and
water were offered and sutures were protected with light
regular antiseptic dressing.
2.3.2. Stent retrieval
On the day of sacrifice, animals were anesthetized
with a similar protocol as mentioned for the stenting
procedure and stents were retrieved. After a midline
laparotomy incision to expose the stented iliac arteries, the
surrounding adventitial connective tissue was separated.
The descending aorta was ligated after securing access of
both the femoral arteries distally. The femoral vessels after
ligation were transected above and the two stented vessels
specimens were separated carefully for bench dissection at
the level of aortic quadrification (Figure 4). The animals
were assigned to follow-up periods of 7, 14, and 21 days to
be sacrificed using thiopentone sodium at 10 mg/kg body
weight through a catheter fixed in the marginal ear vein.
2.3.3. Tissue preparation
The proximal ends of the iliac arteries were tagged with
identification marks and the vessels were excised after
careful separation from the adjacent fascia. Artery with
stent samples were preserved in labeled vials for fixing
with 10% neutral buffered formalin for at least 24 h before
embedding in methyl methacrylate (MMA; E. Merck,
the Netherlands). The stented external iliac arteries
were dehydrated in a graded series of ethanol with three
changes of MMA. The MMA-impregnated specimens
were placed in glass vials and 5 mg/mL of Perkadox 16
di(4-tert butylcyclohexyl) peroxydicarbonate (Akzo Nobel

Figure 4. Retrieved stent.
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Chemicals, India) was added to MMA as a catalyst for
polymerization, and the specimens were oriented in the
vials. After 1 h of vacuum impregnation to remove any
air, the glass vials were carefully closed and the MMA was
polymerized overnight in an oven at 37 °C. Overheating
was prevented by placing the vials in a container with water.
Glass vials were broken, excess MMA was trimmed off,
and sections were cut on a hand-driven rotary microtome
with a tungsten carbide knife (Leica, Germany). Slices of
tissue were kept directly on a slide and then on a hot plate
at 70 °C for 30 min. Stent cross-sections were stained with
hematoxylin and eosin, Martius yellow, scarlet red and
methylene blue, and Masson’s trichrome stains.
2.3.4. Histological and morphometric analysis
Planimetry for calculation of luminal area, intimal
thickness, and medial thickness of the arterial layer was
done using Microimage Lite 4.0 V (Media Cybernetics,
Olympus, USA) software. For each specimen, the
luminal area was obtained by direct measurement of the
area outlined by the endothelium. Intimal and medial
thicknesses were measured at 8 different points and
the mean value was taken as the thickness. The intimal
thickness was measured as the distance between the
internal elastic lamina and endothelium. The medial
thickness was measured as the distance between the internal
and external elastic lamina. The ratio of intimal/medial
thickness was used as the intimal index (16). Dimensions
of the area were described in square millimeters and
the intimal and medial thicknesses in millimeters. The
histopathological endpoints studied by a single, blinded
observer were neointimal hyperplasia, luminal narrowing,

reendothelialization, persistent inflammatory response at
struts, and peristrut fibrin.
2.4. Statistical analysis
The resulting differences in the three groups of 7, 14,
and 21 days were statistically compared for graded
histopathological endpoints between BMS and DES. The
chi-square test and Student t-test were applied to the
observed data.
3. Results
Results were drawn from BMS and SES implantation
in right or left external iliac arteries of all 21 rabbits. In
one rabbit (No. 3), the SES was deployed at the posterior
aorta. Local instillation of lignocaine and papaverine
drops helped in desensitizing the vagus and adequately
dilating the carotid artery to pass the 5-Fr introducer
sheath, respectively. Hind legs of all rabbits were devoid of
ischemic signs, with normal ambulation. Gait was normal
in all the animals after stenting, except in one rabbit (No.
7), where mild lameness in the left hind limb 24 h after
stenting was evident and persisted for 21 days. One rabbit
died due to rupture of the carotid artery during stenting
and was hence excluded from the study. Ligation of the
posterior aorta just before branching, prior to retrieval of
stented arteries, prevented loss of any fibrin or thrombus.
3.1. Histopathology
SES arteries had a larger luminal area (Figure 5) of 1.94
± 0.14 mm2 (P < 0.0001) and lower intimal thickness
(Figure 6) of 0.10 ± 0.01 mm (P = 0.001) as opposed to
BMS arteries. Inflammatory infiltrate (Figure 7) was
present in 62% of the BMS group as compared to 42% of

Figure 5. Neointimal proliferation was more pronounced in bare metal stents (B) as
compared to drug-eluting stents (A).
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Figure 6. Intimal and medial thickness in SES.
Figure 8. Reendothelialization over strut.

Figure 7. Inflammatory infiltration in SES.
Figure 9. Fibrin thrombus in peristrut region.

the SES group (P = 0.01). Reendothelialization (Figure 8)
was present in 90% of stents in the SES as well as BMS
group. There was no significant difference (P = 0.12) in
the peristrut fibrin deposition(Figure 9) between the two
groups with 24% for BMS and 14% for DES (Table).
Analysis was also performed between the two groups
at 7, 14, and 21 days. At 7 and 14 days there was no
significant difference in any of the parameters between
the two groups. At 21 days luminal area was significantly
reduced in animals stented with BMSs (1.89 ± 0.25 mm2)
compared to SESs (2.25 ± 0.28 mm2) (P < 0.01).
4. Discussion
This experimental study done in a rabbit iliac artery model
demonstrates that SESs significantly inhibit neointimal
proliferation and hence preserve arterial luminal area.
The intimal thickness and intimal index were significantly
increased in the BMS group as compared to the SES
group, thus reducing the luminal area. In this study
results are similar to those of other investigators who
demonstrated that SESs inhibit neointimal proliferation

(17,18). A recent study of DESs versus BMSs in patients
undergoing intracoronary bone-marrow mononuclear
cell transplantation following acute myocardial infarction
found a significant reduction of in-stent neointimal
hyperplasia on intravascular ultrasound with DESs as
compared to BMSs (19).
The mechanism by which sirolimus reduces neointimal
formation has been extensively studied. Sirolimus inhibits
the mammalian target of rapamycin (mTOR) and prevents
the degradation of p27kip1, which is a cyclic-dependent
kinase inhibitor that regulates vascular smooth muscle
cell proliferation and migration. This blocks the cell
cycle in the G1 (growth) phase, where RNA and proteins
are synthesized. The cell is then unable to enter the S
(synthesis) phase, thus preventing replication (20,21).
Furthermore, SESs showed a significant reduction in
the early inflammatory response as compared to BMSs.
This again confirms the findings in previously reported
studies (18,22).
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Table. Results of histomorphometry: comparison between BMS and SES.
Parameter

BMS

SES

P-value

Luminal area (mm )

1.73 ± 0.12

1.94 ± 0.14

<0.0001

Intimal thickness (mm)

0.11 ± 0.01

0.10 ± 0.01

0.001

Intimal index (mm)

1.12 ± 0.09

1.02 ± 0.13

0.003

Inflammatory infiltrate

13/21

9/21

0.01

Reendothelialization

19/21

19/21

0.81

Fibrin thrombi

5/21

3/21

0.12

2

Inflammatory cells contribute to the neointimal
thickening by the generation of reactive oxygen
intermediates (23) and production of growth factors (24)
and enzymes like cathepsins, which are capable of breaking
down extracellular constituents and thereby facilitating
smooth muscle cell migration (25).
Our results showed that there was no significant
difference in reendothelialization between the 2 groups.
Similar findings were documented in other studies
(18,22). However, this observation contradicts the
previously reported study where SESs showed delayed
reendothelialization (26). The delayed vascular healing
with SESs is due to their antiproliferative activity as a result
of blocking the cell cycle at the G1 phase (20). Sirolimus
also inhibits the migration and proliferation of endothelial
progenitor cells, thereby contributing to the delay in
reendothelialization (27). Our analysis was done at 7, 14,
and 21 days. A possible explanation for this observation
may be the relatively short period in which the analysis
was performed.
There was no significant difference in the peristrut fibrin
deposition between the two groups in this experiment. In
a pooled analysis of data from four trials comparing SESs
with BMSs, no significant difference was found between
the two in terms of rates of stent thrombosis (28).
Finn et al. (20) reported fibrin thrombus with SESs
more than 1 year after the procedure. Our analysis was
over a short period and hence we may have missed out on
the phenomenon of fibrin thrombus, which is associated
with SESs.
Analysis done at 7 and 14 days showed no significant
differences in any of the parameters between the two
stented groups, but at 21 days the luminal area was

significantly reduced in animals stented with BMSs as
compared to SESs.
The temporal profile of stent healing may be able to
explain this observation. The early response to vascular
injury due to the deployment of stents consists of the
deposition of platelets/fibrin around the struts (1 to
3 days). By the seventh day, the organizing thrombi
surrounding the struts contain smooth muscle cells,
macrophages, lymphocytes, red blood cells, and luminal
endothelial cells. By day 14, fibrin still persists along
with a few chronic inflammatory cells around the struts.
The neointima at this stage contains a few smooth
muscle cells within a proteoglycan-rich matrix. At 28
days, the neointima contains more smooth muscle cells,
proteoglycans, and type III collagen. Macrophages are rare
and fibrin is usually absent. Cell proliferation is greatest
at the seventh day, is reduced to approximately half at 14
days, and returns to a low baseline level by 1 month (13).
In this experimental study, the luminal area was
significantly decreased in the BMS group as compared
to the SES group at the 21st day. We assume that this is
because the antiproliferative effects of sirolimus may be
visible only by the 21st day. Results show that the SES was
effective in inhibiting neointimal proliferation and luminal
narrowing when compared with a BMS in a rabbit external
iliac model.
Acknowledgments
Priti Vani is an employee of Sahajanand Laser Technology,
Ltd., Gujarat, India. The remaining authors have no
conflict of interest to declare. This study was sponsored
by the Muljibhai Patel Society for Research in NephroUrology, Nadiad, India, and Sahajanand Laser Technology,
Ltd., Gujarat, India.

References
1.

374

Assali AR, Moustapha A, Sdringola S, Denktas AE, Willerson
JT, Holmes DR Jr, Smalling RW. Acute coronary syndrome may
occur with in-stent restenosis and is associated with adverse
outcomes (The PRESTO trial). Am J Cardiol 2006; 98: 729–733.

2.

Bennett MR, O’Sullivan M. Mechanisms of angioplasty and
stent restenosis: implications for design of rational therapy.
Pharmacol Ther 2001; 91: 149–166.

PATEL et al. / Turk J Vet Anim Sci
16.

Anderson TJ, Meredith IT, Uehata A, Mudge GH, Selwyn AP,
Ganz P, Yeung AC. Functional significance of intimal thickness
and detected by intravascular ultrasound early and late cardiac
transplantation. Circular 1993; 88: 1093–1100.

17.

Klugherz BD, Llanos G, Lieuallen W, Kopia GA, Papandreou
G, Narayan P, Sasseen B, Adelman SJ, Falotico R, Wilensky
RL. Twenty-eight-day efficacy and pharmacokinetics of the
sirolimus-eluting stent. Coron Artery Dis 2002; 13: 183–188.

18.

Suzuki T, Kopia G, Hayashi S, Bailey LR, Llanos G, Wilensky
RL, Klugherz BD. Stent based delivery of sirolimus reduces
neointimal formation in porcine coronary model. Circulation
2001; 104: 1188–1193.

Oemrawsingh PV, Mintz GS, Schalij MJ, Zwinderman AH,
Jukema JW, Wall EE. Intravascular ultrasound guidance
improves angiographic and clinical outcome of stent
implantation for long coronary artery stenosis: final results of a
randomized comparison with angiographic guidance (TULIP
Study). Circulation 2003; 107: 62–67.

19.

Villa A, Arnold R, Sánchez PL, Gimeno F, Ramos B, Cantero T,
Fernández ME, Sanz R, Gutiérrez O, Mota P et al. Comparison
of neointimal hyperplasia with drug-eluting stents versus
bare metal stents in patients undergoing intracoronary bonemarrow mononuclear cell transplantation following acute
myocardial infarction. Am J Cardiol 2009; 103: 1651–1656.

Serruys PW, Foley DP, Suttorp MJ. A randomized comparison
of the value of additional stenting after optimal balloon
angioplasty for long coronary lesions: final results of the
additional value of NIR stents for treatment of long coronary
lesions (ADVANCE) study. J Am Coll Cardiol 2002; 39: 393–
399.

20.

Finn AV, Nakazawa G, Joner M, Kolodgie FD, Mont EK, Gold
HK, Virmani R. Vascular response to drug eluting stents.
Importance of delayed healing. Arterioscler Thromb Vasc Biol
2007; 27: 1500–1510.

21.

Sun J, Marx SO, Chen H, Poon M, Marks AR, Rabbani LE.
Role for p27Kip1 in vascular smooth muscle cell migration.
Circulation 2001; 103: 2967–2972.

22.

Costa MA, Simon DI. Molecular basis of restenosis and drug
eluting stents. Circulation 2005; 111: 2257–2273.

23.

Chen Z, Keaney JF, Schulz E, Levison B, Shah L, Sakuma M,
Zhang X, Shi C, Hazen SL, Simon DI. Decreased neointimal
formation in Nox-2 deficient mice reveals a direct role for
NADPH oxidase in the response to arterial injury. P Natl Acad
Sci USA 2004; 101: 13014–13019.

24.

Assoian RK, Fleurdelys BE, Stevenson HC, Miller PJ, Madtes
DK, Raines EW, Ross R, Sporn MB. Expression and secretion
of type beta transforming growth factors by activated human
macrophages. P Natl Acad Sci USA 1987; 84: 6020–6021.

25.

Sukhova GK, Sui GP, Simon DI, Chapman HA, Libby P.
Expression of the elastinolytic cathepsins S and K in human
atheroma and regulation of their production in the smooth
muscle cells. J Clin Invest 1998; 102: 576–583.

26.

Frey D, Billinger M, Meier P, Beslac O, Grossenbacher R, Hanni
B, Hess OM. Endothelialization of sirolimus eluting stents with
slow and extended drug release in porcine overstretch model. J
Invasive Cardiol 2008; 20: 631–634.

27.

Fukuda D, Sata M, Tanaka K, Nagai R. Potent inhibitory
effect of sirolimus on circulating vascular progenitor cells.
Circulation 2005; 111: 926–931.

28.

Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW.
A pooled analysis of data comparing sirolimus- eluting stents
with bare metal stents. N Engl J Med 2007; 356: 989–997.

3.

Farb A, Weber DK, Kolodgie FD, Burke AP, Virmani R.
Morphological predictors of restenosis after coronary stenting
in humans. Circulation 2002; 105: 2974–2980.

4.

Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP,
Penn I, Detre K, Veltri L, Ricci D, Nobuyoshi M. A randomized
comparison of coronary-stent placement and balloon
angioplasty in the treatment of coronary artery disease. Stent
Restenosis Study Investigators. N Engl J Med 1994; 331: 496–
501.

5.

Kobayashi Y, De GJ, Kobayashi N. Stented segment length
as an independent predictor of restenosis. J Am Coll Cardiol
1999; 34: 651–659.

6.

7.

8.

Forrester JS, Fishbein M, Helfant R, Fagin J. A paradigm for
restenosis based on cell biology: clues for the development of
new preventive therapies. J Am Coll Cardiol 1991; 17: 758–769.

9.

David RH, Brian GF, Douglas LW. Paradigm shifts in
cardiovascular medicine. J Am Coll Cardiol 2004; 43: 507–512.

10.

Steffel J, Tanner FC. Biological effects of drug-eluting stents in
the coronary circulation. Herz 2007; 32: 268–273.

11.

Iijima R, Mehilli J, Schomig A, Kastrati A. Clinical evidence
on polymer- based sirolimus and paclitaxel eluting stents.
Minerva Cardioangiol 2006; 54: 539–555.

12.

Stone GW, Ellis SG, Cannon L, Mann JT, Greenberg JD, Spriggs
D, O’Shaughnessy CD, DeMaio S, Hall P, Popma JJ et al.
Comparison of a polymer based paclitaxel-eluting stent with
a bare metal stent in patients with complex coronary artery
disease: a randomized controlled trial. JAMA 2005; 294: 1215–
1223.

13.

Virmani R, Kolodgie FD, Farb A, Lafout A. Drug eluting stents:
are human and animal studies comparable? Heart 2003; 89:
133–138.

14.

Farb A, Heller PF, Shroff S, Cheng L, Kolodgie FD, Carter AJ,
Scott DS, Froehlich J, Virmani R. Pathological analysis of local
delivery of paclitaxel via polymer-coated stents. Circulation
2001; 104: 473–479.

15.

LaDisa JF Jr, Meier HT, Olson LE, Kersten JR, Warltier DC,
Pagel PS. Antegrade iliac artery stent implantation for the
temporal and spatial examination of stent-induced neointimal
hyperplasia and alterations in regional fluid dynamics. J
Pharmacol Toxicol Methods 2005; 51: 115–121.

375

